Yao Bilian, Xu Qi, Yamada Yousuke, Angata Kiyohiko, Zhang Yan, Narimatsu Hisashi, Yu Demin, Zhang Xinxin
Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; Department of General Practice, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Antiviral Res. 2025 Feb;234:106077. doi: 10.1016/j.antiviral.2025.106077. Epub 2025 Jan 7.
Recent evidence has indicated that the O-glycosylated PreS2 domain of the middle HBsAg is a distinguishing characteristic that allows the identification of HBsAg of HBV Dane particles and SVPs. This study's objective was to assess the changes in serum O-glycosylated HBsAg levels in CHB patients undergoing ETV or Peg-IFNα treatment.
Our retrospective study enrolled 86 patients with genotype C CHB. We determined the O-glycosylated HBsAg, HBsAg, HBeAg, HBV DNA, and HBV RNA at baseline and during ETV or Peg-IFNα treatment. The correlations between O-glycosylated HBsAg and conventional HBV marker levels were also examined. Furthermore, we performed a ROC analysis to evaluate the predictive value of individual biomarkers for virological response.
At baseline, the serum O-glycosylated HBsAg levels were significantly correlated with the HBsAg (r = 0.754), HBV DNA (r = 0.498), HBeAg (r = 0.404), and HBV RNA (r = 0.399) in HBeAg positive patients. O-glycosylated HBsAg decreased after antiviral therapy. Both O-glycosylated HBsAg and HBsAg were significantly correlated with serum HBV DNA as well as HBV RNA at baseline, while only O-glycosylated HBsAg still correlated with HBV RNA (r = 0.397) in DNA-undetectable patients after ETV therapy. O-glycosylated HBsAg was significantly correlated with HBV RNA (r = 0.846) in DNA-undetectable patients after Peg-IFNα therapy compared to that of HBsAg (r = 0.800).
Serum O-glycosylated HBsAg level decreased during anti-viral therapy and correlated well with conventional HBV markers in HBeAg positive genotype C patients, suggesting that it could be a potential monitoring biomarker in HBV DNA-suppressed patients.
最近有证据表明，乙肝表面抗原（HBsAg）中糖基化的前S2结构域是一个显著特征，可用于识别乙肝病毒（HBV） Dane颗粒和亚病毒颗粒（SVP）的HBsAg。本研究的目的是评估接受恩替卡韦（ETV）或聚乙二醇干扰素α（Peg-IFNα）治疗的慢性乙型肝炎（CHB）患者血清中糖基化HBsAg水平的变化。
我们的回顾性研究纳入了86例C基因型CHB患者。我们在基线以及ETV或Peg-IFNα治疗期间测定了糖基化HBsAg、HBsAg、HBeAg、HBV DNA和HBV RNA。还检测了糖基化HBsAg与传统HBV标志物水平之间的相关性。此外，我们进行了ROC分析，以评估个体生物标志物对病毒学应答的预测价值。
在基线时，HBeAg阳性患者血清中糖基化HBsAg水平与HBsAg（r = 0.754）、HBV DNA（r = 0.498）、HBeAg（r = 0.404）和HBV RNA（r = 0.399）显著相关。抗病毒治疗后糖基化HBsAg降低。在基线时，糖基化HBsAg和HBsAg均与血清HBV DNA以及HBV RNA显著相关，而在ETV治疗后DNA检测不到的患者中，只有糖基化HBsAg仍与HBV RNA相关（r = 0.397）。与HBsAg（r = 0.800）相比，在Peg-IFNα治疗后DNA检测不到的患者中，糖基化HBsAg与HBV RNA显著相关（r = 0.846）。
在抗病毒治疗期间，血清糖基化HBsAg水平降低，且在HBeAg阳性C基因型患者中与传统HBV标志物相关性良好，表明它可能是HBV DNA抑制患者的潜在监测生物标志物。
